Cystic Fibrosis Pipeline Drugs Assessment: Clinical Trials Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018  

Purchase Option

$ 4400
$ 4000
$ 6000

Cystic fibrosis is a inherited disease, enables damage lungs, gastro-intestinal tract and other parts of the body. Cystic fibrosis occur due to defective gene and affects the secreting cells of the body and causes thickening of the body fluids such as muscus, sweat and digestive juices. These body fluids plung up the ducts, tubes and passages, especially in lungs and pancreas. Cystic Fibriosis signs and syptoms develops along with the severity of the disease. Patients may have excess of salt content in sweat than normal and reoccurs pneumonia. Diagnostictests include sweat tests and genetic tests. There is no cure for the disease. Medications are used to treat the disease and reduce the symptoms. Medications may include, mucus thinning agents, antibiotics, anti inflamatory, inhalation brancodialators and others.  

Segmentation: By route of administration, cystic fibrosis pipeline drugs are segmented into

  • Oral
  • Inhalations
  • Parenteral
  • Others

By therapeutic approach, cystic fibrosis pipeline drugs are segmented into

  • CFTR Function Restoring
  • Mucociliary Clearance
  • Anti-Infective
  • Others

By trial phase, Cystic Fibrosis pipeline drugs are segmented into

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By company, Cystic Fibrosis pipeline drugs are segmented into

  • Novartis AG (Switzerland)
  • Galapagos NV (Belgium)
  • Vertex Pharmaceuticals (U.S.)
  • Proteostasis Therapeutics Inc. (U.S.)
  • ProQR Therapeutics (Netherlands)
  • AstraZeneca plc. (UK)
  • Spyryx Biosciences (U.S.)
  • Alaxia (France)
  • Sound Pharmaceuticals Inc. (U.S.)
  • Laurent Pharmaceuticals (Canada)

  Space Analysis: Majority of the drugs under the development for the treatment of the cystic fibrosis are funded by the non-government and government organizations to improve the treatment options. Majority of the companies focusing on development of drugs that restore the CFTR gene function and rest of the therapeutic approaches include Mucociliary Clearance, Nutritional-GI, anti-infective agents and others

  • In October 2016, Celtaxsys announced publication of results demonstrating safety, tolerability and pharmacokinetic & dynamic profile of novel anti-inflammatory medicine, Acebilustat, in phase I trials including CF patients.

  Report Description: Cystic Fibrosis Pipeline Drugs Assessment report studies the various therapeutics under clinical development for cystic fibrosistreatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Cystic Fibrosis pipeline drugsdevelopment. This report studies the dynamics of the Cystic Fibrosis Pipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Cystic Fibrosis pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.  

 

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  1. Executive Summary
  2. Global Cystic Fibrosis Pipeline Drugs Assessment Market Introduction
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market – Taxonomy
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market –Definitions
      • Route of Administration
      • Therapeutic Approach
      • Trial Phase
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market – Competition Landscape
    • Epidemiology
  2. Global Cystic Fibrosis Pipeline Drugs Assessment Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Cystic Fibrosis Pipeline Drugs Assessment Market, By Route of Administration, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Inhalations
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Forecast, By Therapeutic Approach,2013 - 2017 and Forecast, 2018 – 2024
    • CFTR Function Restoring
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Mucociliary Clearance
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Anti-Infective
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Phase I
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase II
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase III
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase IV
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cystic Fibrosis Pipeline Drugs Assessment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Cystic Fibrosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Region, 2018 – 2024
  2. North America Cystic Fibrosis Pipeline Drugs Assessment MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Cystic Fibrosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • North America Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  3. Europe Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Cystic Fibrosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • Europe Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  4. Asia-Pacific Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Cystic Fibrosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • Asia-Pacific Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  5. Latin America Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Cystic Fibrosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • Latin America Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  6. Middle East and Africa Cystic Fibrosis Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Inhalations
      • Parenteral
      • Others
    • Therapeutic Approach Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • CFTR Function Restoring
      • Mucociliary Clearance
      • Anti-Infective
      • Others
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Phase I
      • Phase II
      • Phase III
      • Phase IV
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Cystic Fibrosis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Therapeutic Approach, By Trial Phase, and Country, 2018 – 2024
    • MEA Cystic Fibrosis Pipeline Drugs Assessment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Novartis AG (Switzerland)
      • Galapagos NV (Belgium)
      • Vertex Pharmaceuticals (U.S.)
      • Proteostasis Therapeutics Inc. (U.S.)
      • ProQR Therapeutics (Netherlands)
      • AstraZeneca plc. (UK)
      • Spyryx Biosciences (U.S.)
      • Alaxia (France)
      • Sound Pharmaceuticals Inc. (U.S.)
      • Laurent Pharmaceuticals (Canada)
  1. Research Methodology
  2. Key Assumptions and Acronyms

Disclaimer

The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.

  • Novartis AG (Switzerland)
  • Galapagos NV (Belgium)
  • Vertex Pharmaceuticals (U.S.)
  • Proteostasis Therapeutics Inc. (U.S.)
  • ProQR Therapeutics (Netherlands)
  • AstraZeneca plc. (UK)
  • Spyryx Biosciences (U.S.)
  • Alaxia (France)
  • Sound Pharmaceuticals Inc. (U.S.)
  • Laurent Pharmaceuticals (Canada)

Adjacent Markets